Cloud-Clone rolls out liver-disease research toolkit

Cloud-Clone Corp. says its integrated portfolio of assays, primary cells and animal models is designed to support hepatology research from biomarker discovery through pre-clinical validation. The company is targeting global demand for better tools as viral hepatitis, fatty liver disease and related disorders continue to drive heavy disease burden.

Why it matters: - Liver disease remains a major global public-health burden, with chronic hepatitis B and non-alcoholic fatty liver disease driving demand for better research tools. - Cloud-Clone’s end-to-end portfolio is designed to help researchers move from molecular studies to pre-clinical validation using one integrated workflow. - The company says the platform can support biomarker discovery, mechanistic research and therapeutic development for precision-medicine programs.

What happened: - Cloud-Clone Corp. unveiled a liver-disease research product portfolio that spans molecular assays, recombinant proteins, antibodies, primary cells and animal models. - The announcement was issued from Houston on Sept. 21, 2026. - The company said the portfolio is built to support hepatology research across molecular, cellular and whole-animal levels. - More information is available in Cloud-Clone’s announcement.

The details: - Cloud-Clone’s assay lineup includes ELISA kits for markers tied to liver injury and disease, including albumin, ALT, AST, hyaluronic acid, type-IV collagen and TGF-β1. - The ELISA kits are designed for serum, plasma, cell-culture supernatant and tissue homogenate. - The company says the assays are validated for human, mouse and rat specimens. - Cloud-Clone also offers multiplex panels for flow cytometry and Luminex platforms, including product IS135-35. - IS135-35 uses 25 μL of starting sample and measures ALP, ALT, AST, ALB and LDH at the same time. - The protein portfolio includes human and murine cytokines and metabolic-regulatory proteins such as IL-6, TNF-α, leptin, resistin, FGF21, HGF and LBP. - Cloud-Clone says the proteins are produced with E. coli, yeast and mammalian expression systems and are high-purity with low endotoxin levels. - The antibody portfolio targets CK18, CK19, HNF4α, CD31, CD68, α-SMA, Desmin and CHI3L1. - Those antibodies are validated for Western blot, immunohistochemistry and immunofluorescence. - Custom services include recombinant-protein production, monoclonal and polyclonal antibody generation, purification and HRP or biotin labeling. - The cell portfolio includes fresh and cryopreserved primary hepatocytes from human, rabbit, canine, rat and mouse. - Cloud-Clone says optimized isolation and cryopreservation protocols are used to maintain post-thaw viability. - The company also offers culture media for long-term studies in drug interaction, toxicology and metabolism. - For animal studies, Cloud-Clone provides carbon-tetrachloride-induced hepatic-fibrosis models that can progress from fibrosis to early-stage cirrhosis. - The company says alcohol-associated liver-disease and autoimmune-hepatitis models are also being optimized. - Cloud-Clone says the primary-cell and animal-model products are delivered with ethical review documentation and quality-control records.

Between the lines: - The pitch is about workflow integration, not just individual reagents. - Cloud-Clone is positioning itself as a one-stop supplier for researchers who need consistent tools across discovery, validation and submission-ready pre-clinical work. - The emphasis on validated species coverage, sample compatibility and documentation suggests the company is targeting translational labs that need reproducible data.

What's next: - Cloud-Clone says it will keep investing in hepatology-focused R&D. - The company plans to expand its product catalogue and maintain quality-control benchmarks. - Cloud-Clone also says it will continue broadening its integrated portfolio of assays, primary cells and pre-clinical animal models to support liver-disease research worldwide.

The bottom line: - Cloud-Clone is betting that liver-disease researchers want more than single products — they want a coordinated toolkit that carries projects from bench biology to pre-clinical testing.